BOSTON: bluebird bio, Inc. (NASDAQ: BLUE) announced today that it has reached a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP, in collaboration with a team of biotech executives. The transaction will see David Meek, former CEO of Mirati Therapeutics and Ipsen, take over as…